Teriparatide (Forteo, Bonsity)
Recombinant fragment of human parathyroid hormone (PTH 1-34) used as an anabolic agent in osteoporosis.
At a glance
What it is: Recombinant fragment of human parathyroid hormone (PTH 1-34) used as an anabolic agent in osteoporosis..
Primary research applications:
- Severe postmenopausal osteoporosis
- Glucocorticoid-induced osteoporosis
- Male osteoporosis with high fracture risk
Editorial summary: Teriparatide was the first true bone-anabolic agent approved for osteoporosis, demonstrating that intermittent PTH stimulation can build new bone rather than merely slowing loss. It transformed osteoporosis pharmacology and remains a reference point for any peptide-based hormone-replacement strategy.
- Class / structure
- Recombinant human PTH(1-34) — N-terminal 34 amino acids of parathyroid hormone
- Half-life
- ≈ 1 hour (subcutaneous)
- First described
- Recombinant production developed in the 1990s
- Regulatory status
- FDA-approved (2002)
What is Teriparatide?
Teriparatide is the recombinant N-terminal 34-amino-acid fragment of human parathyroid hormone, retaining the receptor-binding region while omitting the C-terminal portion not required for activity.
Discovery and development
Teriparatide was approved by the FDA in 2002 (as Forteo, Eli Lilly), based on the landmark Fracture Prevention Trial published in NEJM in 2001. It established a counterintuitive principle: chronic high PTH causes bone resorption, but pulsatile (once-daily injection) PTH stimulation produces net bone formation.
Mechanism of action
PTH receptor stimulation activates osteoblasts and osteoclasts. Continuous high PTH (as in primary hyperparathyroidism) drives net bone resorption. Pulsatile PTH from once-daily injection drives net bone formation — a temporal pharmacology that took years to characterize and remains a teaching example of how dosing frequency can determine drug effect.[1]
Pharmacokinetics
Once-daily subcutaneous injection. Peak plasma concentrations occur within 30 minutes; half-life is approximately 1 hour. The brief pulsatile signal is critical to the anabolic versus catabolic switch.
What the research shows
The peer-reviewed literature on Teriparatide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Reduces vertebral fracture risk in osteoporosis | Fracture Prevention Trial | Supported |
| Reduces non-vertebral fracture risk | Same trial | Supported |
| Builds new bone rather than just slowing loss | Histomorphometric and BMD evidence | Supported |
| Use is limited to two years | FDA labeling, based on rodent osteosarcoma signal | Supported |
Reported user experiences
How the research describes administration
Once-daily subcutaneous injection in the thigh or abdomen. Total duration of use is limited to approximately two years lifetime due to a rodent osteosarcoma signal observed in toxicology studies.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Teriparatide established the principle that selective, pulsatile peptide signaling can drive net bone formation — transforming osteoporosis pharmacology and demonstrating that hormone-replacement strategies built on natural peptides can produce clinically transformative outcomes when the dosing biology is right.
Frequently asked questions
Why is teriparatide limited to two years of use?
Rodent toxicology studies showed dose-dependent osteosarcoma. The FDA limited human use accordingly. Long-term human pharmacovigilance has not consistently demonstrated the same signal in humans, but the labeling restriction remains.
Is teriparatide the same as PTH?
It is the recombinant N-terminal 34-amino-acid fragment of human PTH (PTH 1-34). The full-length PTH hormone has 84 amino acids; teriparatide retains the receptor-binding region only.
References
- Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007;40(6):1434-1446. https://pubmed.ncbi.nlm.nih.gov/17517365/
- Neer RM, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441. https://pubmed.ncbi.nlm.nih.gov/11346808/